Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2021 Aug 5.
Published in final edited form as: Synlett. 2020 Nov 10;32(6):601–604. doi: 10.1055/a-1308-0370

Stereoselective Synthesis of (4S,5S)-5-Vinyloxazolidin-2-one-4-carboxylate as a β-Vinylserine Synthetic Equivalent by Vinyl Grignard Addition to an N-Tosyl Version of Garner’s Aldehyde

Ernest G Nolen 1, Yuqi M Cao 1, Brynn D Lewis 1, Madison H Powers 1, Andrew W Thompson 1, John M Bennett 1
PMCID: PMC8341458  NIHMSID: NIHMS1699731  PMID: 34366570

Abstract

A highly efficient synthesis of a β-vinylserine synthetic equivalent is reported that exploits the stereodirecting effect of the N-toluenesulfonamide in an anti-diastereoselective (8.5:1) vinyl Grignard addition to an analogue of Garner’s aldehyde. Both aryl and alkyl Grignards are shown to give increased anti-selectivity compared with N-Boc Garner’s aldehyde.

Keywords: vinylserine, alkenyl amino acid, Garner aldehyde, oxazolidinones

Graphical Abstract

graphic file with name nihms-1699731-f0006.jpg


As part of our synthetic work directed toward glycopeptide mimetics, we required a suitably protected (2S,3S)-β-vinylserine (β-VSer) for use as a synthetic building block. Many noncanonical amino acids have been incorporated into protein and peptide structures to interrogate various cellular functions.1 In particular, alkenyl amino acids incorporated into peptides have proven to be useful for peptide stapling by a cross-metathesis reaction to afford conformationally restricted peptidomimetics.2 In addition, Zhang and van der Donk have examined the effect of direct alkenyl amino acid incorporation.3 They incorporated a diastereomer of our desired β-VSer (referred to as a threonine analogue) into a peptide sequence of lacticin synthetase to examine substrate selectivity toward dehydration reactions. The pentenoic backbone of β-VSer itself is also a common scaffold for dipeptide isosteres,4 which have been investigated as enzyme inhibitors and as receptor antagonists.5 This platform has also been a versatile synthetic intermediate for preparing sphingomyelin analogues6 and glycosidase inhibitors such as the deoxynojirimycins.7 It has also served as a building block for antitumor agents such as 2-epi-pachastrissamine8 or for glycopeptide9 and β-lactam antibiotics.10 For our purposes, we sought to elaborate the β-VSer alkene through cross-metathesis and/or Trost–Tsuji π-allylic alkylation chemistry for the development of novel glycopeptides.

Given the versatility and interest in this simple building block, we elected to exploit an oxazolidinone scaffold 1 as a β-VSer synthetic equivalent in which both the amine and the hydroxy functions are simultaneously protected (Scheme 1). Although there are excellent reports on carbamate cyclizations11 and an allylic C–H amination12 that yield trans-4,5-disubstituted oxazolidinones stereospecifically, our studies required a cis-oxazolidinone. cis-4,5-Disubstituted oxazolidinones of this sort are known and are commonly derived from anti-2-aminopent-4-en-1,3-diols such as 2.

Scheme 1.

Scheme 1

Target β-vinylserine (β-VSer) synthetic equivalent 1 and precursor

Both vinyl oxazolidinones and functionalized 2-aminopent-4-en-1,3-diols are valuable synthetic intermediates that have been used to prepare numerous natural products and medicinal targets, as discussed above. Although synthetic approaches from carbohydrates,13 azide epoxide openings,6a and chiral glycine enolate aldols14 are available, the more common synthetic approaches entailing nucleophilic additions to α-amino-β-hydroxy aldehydes or ketones provide varying degrees of control of stereochemistry (Scheme 2).

Scheme 2.

Scheme 2

Approaches to cis-oxazolidinones

A survey of the literature indicated one could proceed by a vinyl Grignard addition onto the well-known D-serine-derived Boc-protected Garner’s aldehyde15 or the OTBS-Boc-serinal 4,7a,10 followed by an intramolecular cyclization onto the Boc group to form an oxazolidinone. The Grignard approach has been widely used,7b,9,16 but is limited due to the selectivity of the Grignard addition; this led Herold to develop a three-step approach employing trimethylsilyl acetylide additions for improved anti-stereoselectivity.17 Although the tert-butyl(dimethyl)silyl ether substrate 4 gives 5 directly, it results in an undesirable 1:2 anti/syn diastereomeric ratio.7a The typical anti-selectivity for vinyl addition to Garner’s aldehyde is reported to range from 3:116a to 6:1 anti/syn, and experimental details indicate that additional purification by chromatography is necessary. From the Grignard product of Garner’s aldehyde, hydrolysis of the N,O-acetal and selective protection of the primary hydroxy groups is needed, followed by formation of the oxazolidinone by a base-induced intramolecular cyclization onto the tert-butyl carbamate to afford 6.18 In an improvement to these early approaches, the Weinreb amide 7 of a protected D-serine, available in four steps, has been employed to form an enone upon addition of vinylmagnesium bromide; this enone can be stereoselectively reduced with Li(t-BuO)3AlH in ethanol giving 5 with a 10:1 preference toward the anti-diastereomer.19

Here, we report a highly selective alternative approach in which the N-tosylamide 8 is used as a stereodirecting orthogonal protecting group; this approach is complementary to the approaches discussed above.

For our purpose, we had concerns about the N-Boc protecting group due to its potential for neighboring-group participation in our planned synthetic manipulations; we therefore initially desired an N-tosyl protected nitrogen on the oxazolidinone 9. Although one could simply tosylate the known oxazolidinone 6 to give 9, we considered initiating our synthesis with the acyclic silyl-protected N-tosyl-D-Ser20 or the N-tosyl equivalent of Garner’s aldehyde.21 Vinyl Grignard additions to N-sulfonyl-protected acyclic amino acids are not usually selective. Literature reports suggest that additions to the aldehydes of TsNH-Ala22 and TsNH-Phe23 give poor diastereoselectivities (2:3 anti/syn and 2:1 with the major isomer not identified, respectively). Given the poor selectivity of additions to acyclic amino aldehydes, we opted to pursue the use of a toluenesulfonamide derivative of Garner’s aldehyde 8. Surprisingly, no Grignard chemistry has been reported on this aldehyde. We found that vinylmagnesium bromide added cleanly to give a >95% yield24 (Scheme 3) and was more selective than the N-Boc-protected Garner’s aldehyde, giving the anti-allylic alcohol 10 with an 8.5:1 dr before chromatography. The use of LiCl as an additive in the vinylmagnesium bromide reaction did not alter the results. Although some trial runs using vinylmagnesium chloride directly did show >10:1 diastereoselectivity, these seemed highly dependent on the commercial source and age of the reagent. Conveniently, no rotamers are observed in the NMR spectra of the tosylamides, unlike the Boc-derivatives, making their interpretation more straightforward; moreover, TLC visualization and chromatographic detection is aided by the UV activity of the aromatic sulfonamide.

Scheme 3.

Scheme 3

Synthesis of β-VSer derivatives 12 and 14; pNs = 4-O2NC6H4SO2.

The improved diastereoselectivity can be partially explained by examining the LUMO energies of the reactive Felkin–Anh conformations (Scheme 4). With the N-sulfonamide there is a strong preference for the C–NTs bond of 9b to lie perpendicular to the plane defined by the aldehyde carbonyl as opposed to the C–CH2O bond in 9a. The LUMO of 9a is 3.46 kcal mol−1 higher in energy than that of 9b, as determined by ground-state gas-phase DFT calculations using an ω−897XD hybrid GGA functional. This predicts that nucleophilic approach should favor attack on 9b, leading to the 2,3-anti-product. In contrast, the N-Boc derivative has a smaller LUMO energy difference (2.77 kcal mol−1) between the two Felkin–Anh conformations, so it would not be expected to be as stereoselectively based on this analysis.

Scheme 4.

Scheme 4

Felkin–Anh depiction of nucleophilic attacks

The trend favoring the 2,3-anti-diastereomer is also observed for aryl and methyl Grignards, with >7:1 ratios being observed (Table 1). Interestingly, ethyl Grignard also afforded an 8:1 selectivity toward the anti-product, which is a near reversal of the syn-preference observed by Joullié and others.25 The 2,3-syn-selectivity has been suggested to arise from chelation to the Boc carbonyl oxygen,26 which might contribute to our observed anti-preference with the less chelation-prone tosylamide. Finally, the allyl Grignard gave poor selectivity in this reaction.

Table 1.

Comparison of Grignard Additions to 8 and to Garner’s Aldehyde

graphic file with name nihms-1699731-t0001.jpg
Entry R Pg = Ts anti/syna Yieldb (%) Pg = Boc anti/syn Ref.
1 vinyl 8.5:1 95 3–6:1 7b,9,16
2 Ph 12:1 70 1.5–5:1 27,25b
3 4-MeOC6H4 14:1 n.d.c 5:1d 27
4 Me 7:1 93 2:1 25a
5 Et 8:1 87e 1:9 25a
6 All 1:1.6 94 1.5:1 28
a

Determined by 1H NMR integration on the crude sample or after hydrolysis to the diol.

b

The crude product contained 1–4% of starting aldehyde.

c

Not determined due to contamination by anisole. Hydrolysis gave the diol in 59% yield over two steps.

d

Aryllithium rather than Grignard.

e

anti-Configuration confirmed by comparison with hydrogenated 10.

For most of the N-tosyl Grignard products, we observed significant decomposition to the diol or rearrangement to dioxolanes on silica gel chromatography, so for 10, the crude product was always carried forward. Acidic hydrolysis of the N,O-acetal by using 4-toluenesulfonic acid in an ethanol/methanol mixture gave chromatographically pure diol 3,24 which could be selectively protected at the primary hydroxy group with tert-butyl(dimethyl)silyl chloride to supply 11 in 80% over three steps from 8. Note that this silylation is much more easily achieved than that of the similar Boc-amine diol 2 derived from Garner’s aldehyde, which tends to give disilylation products if great care is not taken.

To confirm our stereochemical assignment of the vinyl addition, the known oxazolidinone29 9 was formed in 75% yield from 11 by using triphosgene and pyridine. Unfortunately, the 1H NMR spectrum reported in the literature was not sufficiently resolved to permit comparison of coupling constants, but, in general, the H-4 to H-5 coupling (oxazolidinone numbering) can be easily used to distinguish between the cis- and trans-diastereomers, with cis J4,5 ≈ 7 Hz and the trans J4,5 ≈ 4 Hz.30 Oxazolidinone 9 has J4,5 of 7.6 Hz, indicative of a cis-relationship. In addition, removal of the toluenesulfonyl protecting group could be accomplished in good yield (83%) by using Na/naphthalene in 1,2-dimethoxyethane, and the cis-coupling constant between H5 at δ = 5.04 ppm and H4 at δ = 3.83 ppm of oxazolidinone 6 was revealed to be 8.1 Hz, matching that reported by Ibuka,18 and thereby confirming our assignment of the anti-diastereomer 10 from the Grignard chemistry. Note that this synthetic route to 6 via N-tosyl serinal 8 is a significant improvement compared with previously reported Grignard chemistry.

In our case, we had no desire to remove the N-tosyl protection; instead, we sought to deprotect the primary hydroxy and to oxidize it to a carboxylic acid to form our β-VSer synthetic equivalent. Although there are reports of both steps being achieved in one pot with KF, Jones reagent, or similar compounds31 we found it better to do this in a stepwise manner by using HCl and MeOH to remove the silyl protection in 92% yield, and subsequent Jones oxidation to supply methyl ester 12 in 82% yield after diazomethane treatment. Unfortunately, attempts at oxidation with TEM-PO-type reagents did not give a complete reaction, giving yields of around 50% in our hands.

Although we desired the N-tosyl protection, we recognize its versatility is limited for some cases, so we demonstrated that the final steps can also be carried out with a p-nosyl-protected nitrogen. From 6, the para-nosyl group can be introduced using sodium hydride in THF to give 13 in 90% yield. Similar reactions have been reported to run in DMF and to give concomitant silyl ether cleavage,29 but in our case a mixture was always observed. Therefore, we removed the silyl ether under acidic conditions and employed a Jones oxidation, as described earlier for 12, to give 14 in similar yields.

In summary, an efficient synthesis of a β-vinyl serine (β-VSer) synthetic equivalent is reported that exploits the stereodirecting effect of the N-toluenesulfonamide group in a highly diastereoselective vinyl Grignard addition.

Supplementary Material

Supporting Info Synlett 2021 Nolen

Acknowledgment

The authors thank the University of Florida’s Mass Spectrometry Research and Education Center for the HRMS measurements.

Funding Information

This work was supported by the National Institutes of Health (GM123534-01A1) and the National Science Foundation (MRI 1726308).National Science Foundation (MRI 1726308)National Institutes of Health (GM123534-01A1)

Footnotes

Supporting Information

Supporting information for this article is available online at https://doi.org/10.1055/a-1308-0370.

References and Notes

  • (1).Ngo JT; Tirrell DA Acc. Chem. Res 2011, 44, 677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (2).(a) Blackwell HE; Grubbs RH Angew. Chem. Int. Ed 1998, 37, 3281. [DOI] [PubMed] [Google Scholar]; (b) Schafmeister CE; Po J; Verdine GL J. Am. Chem. Soc 2000, 122, 5891. [Google Scholar]; (c) Aillard B; Robertson NS; Baldwin AR; Robins S; Jamieson AG Org. Biomol. Chem 2014, 12, 8775. [DOI] [PubMed] [Google Scholar]; (d) Yeo DJ; Warriner SL; Wilson AJ Chem. Commun 2013, 49, 9131. [DOI] [PubMed] [Google Scholar]
  • (3).Zhang X; van der Donk WA J. Am. Chem. Soc 2007, 129, 2212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (4).Ibuka T; Habashita H; Otaka A; Fujii N; Oguchi Y; Uyehara T; Yamamoto YJ Org. Chem 1991, 56, 4370. [Google Scholar]
  • (5).(a) Oishi S; Narumi T; Ohno H; Otaka A; Fujii N Yuki Gosei Kagaku Kyokaishi 2008, 66, 846. [Google Scholar]; (b) Venkatesan N; Kim BH Curr. Med. Chem 2002, 9, 2243. [DOI] [PubMed] [Google Scholar]
  • (6).(a) Hakogi T; Yamamoto T; Fujii S; Ikeda K; Katsumura S Tetrahedron Lett 2006, 47, 2627. [Google Scholar]; (b) Yamamoto T; Hasegawa H; Hakogi T; Katumura S Org. Lett 2006, 8, 5569. [DOI] [PubMed] [Google Scholar]; (c) Wisse P; de Geus MAR; Cross G; van den Nieuwendijk AMCH; van Rooden EJ; van den Berg RJBHN; Aerts JMFG; van der Marel GA; Codée JDC; Overkleeft HS J. Org. Chem 2015, 80, 7258. [DOI] [PubMed] [Google Scholar]
  • (7).(a) Knight JG; Tchabanenko K Tetrahedron 2003, 59, 281. [Google Scholar]; (b) Takahata H; Banba Y; Sasatani M; Nemoto H; Kato A; Adachi I Tetrahedron 2004, 60, 8199. [Google Scholar]
  • (8).Lee D Synlett 2012, 23, 2840. [Google Scholar]
  • (9).Wang B; Liu Y; Jiao R; Feng Y; Li Q; Chen C; Liu L; He G; Chen GJ Am. Chem. Soc 2016, 138, 3926. [DOI] [PubMed] [Google Scholar]
  • (10).Murphy-Benenato KE; Dangel B; Davis HE; Durand-Réville TF; Ferguson AD; Gao N; Jahic H; Mueller JP; Manyak EL; Quiroga O; Rooney M; Sha L; Sylvester M; Wu F Zambrowski M, Zhao SX. 2015, 6, 537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (11).(a) Robertson J; Abdulmalek E Tetrahedron Lett 2009, 50, 3516. [Google Scholar]; (b) Kim H; Yoo D; Choi SY; Chung YK; Kim YG Tetrahedron: Asymmetry 2008, 19, 1965. [Google Scholar]; (c) Martín R; Moyano A; Pericàs MA; Riera A Org. Lett 2000, 2, 93. [DOI] [PubMed] [Google Scholar]; (d) Amador M; Ariza X; Garcia J; Sevilla S Org. Lett 2002, 4, 4511. [DOI] [PubMed] [Google Scholar]
  • (12).Fraunhoffer KJ; White MC J. Am. Chem. Soc 2007, 129, 7274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (13).Lee JH; Kang JE; Yang MS; Kang KY; Park KH Tetrahedron 2001, 57, 10071. [Google Scholar]
  • (14).(a) Kazmaier U; Pähler S; Endermann R; Häbich D; Kroll H-P; Riedl B Bioorg. Med. Chem 2002, 10, 3905. [DOI] [PubMed] [Google Scholar]; (b) Dubreuil D; Pipelier M; Micouin L; Lecourt T; Lacone V; Bonneville M; Lependu J; Turcot-Dubois A-L WO 2008/047249, 2008. [Google Scholar]
  • (15).(a) Garner P; Park JM J. Org. Chem 1988, 53, 2979. [Google Scholar]; (b) Garner P Tetrahedron Lett 1984, 25, 5855. [Google Scholar]
  • (16).(a) Passiniemi M; Koskinen AMP Beilstein J. Org. Chem 2013, 9, 2641. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Coleman RS; Carpenter AJ Tetrahedron Lett 1992, 33, 1697. [Google Scholar]; (c) Ojima I; Vidal ES J. Org. Chem 1998, 63, 7999. [Google Scholar]; (d) Kumar G; Kaur S; Singh V Helv. Chim. Acta 2011, 94, 650. [Google Scholar]; (e) Ghosal P; Shaw AK Tetrahedron Lett 2010, 51, 4140. [Google Scholar]; (f) Bhabak KP; Proksch D; Redmer S; Arenz C Bioorg. Med. Chem 2012, 20, 6154. [DOI] [PubMed] [Google Scholar]
  • (17).Herold J Helv. Chim. Acta 1988, 71, 354. [Google Scholar]
  • (18).Ibuka T; Mimura N; Aoyama H; Akaji M; Hono H; Miwa Y; Taga T; Nakai K; Tamamura H; Fujii N; Yamamoto YJ Org. Chem 1997, 62, 999. [DOI] [PubMed] [Google Scholar]
  • (19).(a) Myeong I-S; Kim JS; Park M-G; Jeon H-H; Jung C; Lee Y-T; Ham W-H Synthesis 2018, 50, 2058. [Google Scholar]; (b) Yamamoto T; Hasegawa H; Hakogi T; Katsumura S Org. Lett 2006, 8, 5569. [DOI] [PubMed] [Google Scholar]; (c) Jin T; Mu Y; Kim J-S; Park S-H; Jin X; Kang J-C; Oh C-Y; Ham W-H Synth. Commun 2014, 44, 2401. [Google Scholar]
  • (20).(a) Jurczak J; Golebiowski A Chem. Rev 1989, 89, 149. [Google Scholar]; (b) Knight JG; Ainge SW; Harm AM; Harwood SJ; Maughan HI; Armour DR; Hollinshead DM; Jaxa-Chamiec AA J. Am. Chem. Soc 2000, 122, 2944. [Google Scholar]
  • (21).(a) Çelebi-Ölçüm N; Lam Y.-h.; Richmond E; Ling; Smith AD; Houk KN Angew. Chem. Int. Ed 2011, 50, 11478. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Richmond E; Ling KB; Duguet N; Manton LB; Çelebi-Ölçüm N; Lam Y-H; Alsancak S; Slawin AMZ; Houk KN; Smith AD Org. Biomol. Chem 2015, 13, 1807. [DOI] [PubMed] [Google Scholar]
  • (22).Gryko D; Urbańczyk-Lipkowska Z; Jurczak J Tetrahedron: Asymmetry 1997, 8, 4059. [Google Scholar]
  • (23).Reginato G; Pezzati B; Ienco A; Manca G; Rossin A; Mordini AJ Org. Chem 2011, 76, 7415. [DOI] [PubMed] [Google Scholar]
  • (24).N-[(1R,2S)-2-Hydroxy-1-(hydroxymethyl)but-3-en-1-yl]-4-methylbenzenesulfonamide (3); A 1.6 M solution of vinylmagnesium chloride in THF (18.9 mmol, 11.8 mL, 4 equiv) was added dropwise over 30 min to a solution of the aldehyde 8 (1.34 g, 4.74 mmol) in THF (44 mL) at −40 °C. The solution was then warmed to 0 °C and stirred overnight at rt. The solution was then poured into cold sat. aq NH4Cl and extracted with EtOAc (×3). The combined organic extracts were washed with brine, dried (Na2SO4), filtered, and concentrated to give crude product 10 as a colorless viscous oil; yield: ~1.5 g. 1H NMR (400 MHz, CDCl3): δ = 7.85–7.72 (m, 2 H), 7.39–7.29 (m, 2 H), 5.95–5.76 (m, 1 H), 5.49–5.23 (m, 2 H), 4.47 (td, J = 5.2, 2.4 Hz, 1 H), 4.01 (dd, J = 9.2, 4.2 Hz, 1 H), 3.91–3.65 (m, 2 H), 2.82 (d, J = 5.4 Hz, 1 H), 2.46 (s, 3 H), 1.72 (s, 3 H), 1.62–1.47 (m, 3 H); To a solution of the crude vinyl alcohol 10 (~4.74 mmol) in MeOH (80 mL) and EtOH (80 mL) at r.t. was added TsOH·H2O (180 mg 0.95 mmol, 2 equiv). The solution was stirred overnight then concentrated to half its original volume, diluted with EtOAc (400 mL), and washed with 2:1 sat. aq NaHCO3–H2O (100 mL). The aqueous phase was back-extracted with EtOAc, and the combined organic extracts were washed with brine (×2) and dried (Na2SO4). Flash column chromatography (silica gel, 50–75% EtOAc–hexanes) gave an off-white solid; yield: 1.00 g (80%); mp 75–76 °C; Rf = 0.20 (50% EtOAc–hexanes).; 1H NMR (400 MHz, CDCl3): δ = 7.81 (d, J = 8.3 Hz, 2 H), 7.34 (d, J = 8.3 Hz, 2 H), 5.82 (ddd, J = 17.3, 10.6, 5.1 Hz, 1 H), 5.44 (d, J = 7.9 Hz, 1 H), 5.37 (bd, J = 17.2, Hz, 1 H), 5.37 (bd, J = 10.6 Hz, 1 H), 4.29 (m, 1 H), 3.86 (dt, J = 11.6, 3.6 Hz, 1 H), 3.51 (ddd, J = 11.5, 7.8, 3.8 Hz, 1 H), 3.28 (dt, J = 7.9, 3.7 Hz, 1 H), 2.54 (d, J = 10.6 Hz, 1 H), 2.46 (s, 3 H), 2.25 (dd, J = 7.8, 4.1 Hz, 1 H). 13C NMR (100 MHz, CDCl3): δ = 143.8, 137.4, 136.4, 129.9, 127.1, 117.2, 74.8, 61.8, 57.3, 21.6. HRMS (ESI-TOF): m/z [M + Na]+ calcd for C12H17NNaO4S: 294.0776; found: 294.0770.
  • (25).(a) Ageno G; Banfi L; Cascio G; Guanti G; Manghisi E; Riva R; Rocca V Tetrahedron 1995, 51, 8121. [Google Scholar]; (b) Williams L; Zhang Z; Shao F; Carroll PJ; Joullié MM Tetrahedron 1996, 52, 11673. [Google Scholar]
  • (26).Mengel A; Reiser O Chem. Rev 1999, 99, 1191. [DOI] [PubMed] [Google Scholar]
  • (27).(a) Malins LR; Payne RJ Org. Lett 2012, 14, 3142. [DOI] [PubMed] [Google Scholar]; (b) Giltrap AM; Haeckl FPJ; Kurita KL; Linington RG; Payne RJ J. Org. Chem 2018, 83, 7250. [DOI] [PubMed] [Google Scholar]
  • (28).Bayquen AV; Read RW Tetrahedron 1996, 52, 13467. [Google Scholar]
  • (29).Knight JG; Lawson IM; Johnson CN Synthesis 2006, 227. [Google Scholar]
  • (30).(a) Myeong I-S; Lee Y-T; Lee S-H; Jung C; Kim J-S; Park S-H; Kang J; Lee S-J; Ye I-H; Ham W-H Tetrahedron: Asymmetry 2017, 28, 1053. [Google Scholar]; (b) Zamani F; Pyne SG; Hyland CJT Org. Chem 2017, 82, 6819. [DOI] [PubMed] [Google Scholar]
  • (31).(a) Liu H-J; Han I-S Synth. Commun 1985, 15, 759. [Google Scholar]; (b) Laib T; Chastanet J; Zhu JJ Org. Chem 1998, 63, 1709. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Info Synlett 2021 Nolen

RESOURCES